Mebendazole further complements these therapeutic attributes by evoking a higher level of anti-neoplastic cytotoxic against chemotherapeutic resistant mammary adenocarcinoma (SKBr-3) when applied in combination with both gemcitabine-(C4-amide)-[anti-EGFR] with epirubicin-(C3-amide)-[anti-HER2/neu] compared to the dual-combination of only the two covalent immunochemotherapeutics. Here, ERBB2 is linked to breast adenocarcinoma.